Osteoprotegerin is independently associated with metabolic syndrome and microvascular complications in type 2 diabetes mellitus

Diabetes and Vascular Disease Research

Volumn 11, Issue 5, 2014, Pages 359-362

  Tavintharan, S ^a   Pek, Li Ting Sharon ^a   Liu, Jian Jun ^a   Ng, Xiao Wei ^a   Yeoh, Lee Ying ^a   Su Chi, Lim ^a   Chee Fang, Sum ^a  

^a KHOO TECK PUAT HOSPITAL   (Singapore)

Author keywords

biomarkers; diabetes; macrovascular; Metabolic syndrome; microvascular

Indexed keywords

OSTEOPROTEGERIN; BIOLOGICAL MARKER; TNFRSF11B PROTEIN, HUMAN;

ADULT; ARTICLE; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DIET RESTRICTION; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTOR VARIABLE; PREVALENCE; RISK FACTOR; AGED; BLOOD; CHI SQUARE DISTRIBUTION; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; MICROCIRCULATION; MICROVASCULATURE; MIDDLE AGED; PATHOPHYSIOLOGY; PREDICTIVE VALUE; RISK; SINGAPORE; STATISTICAL MODEL; UPREGULATION; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LOGISTIC MODELS; MALE; METABOLIC SYNDROME X; MICROCIRCULATION; MICROVESSELS; MIDDLE AGED; ODDS RATIO; OSTEOPROTEGERIN; PREDICTIVE VALUE OF TESTS; PREVALENCE; RISK FACTORS; SINGAPORE; UP-REGULATION; YOUNG ADULT;

EID: 84906059879     PISSN: 14791641     EISSN: 17528984     Source Type: Journal    
DOI: 10.1177/1479164114539712     Document Type: Article

References (12)

1. Collin-Osdoby P. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circ Res. 2004 ; 95: 1046-1057
2. Bucay N, Sarosi I, Dunstan CR, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998 ; 12: 1260-1268
3. Kiechl S, Schett G, Wenning G, et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation. 2004 ; 109: 2175-2180
4. Nabipour I, Kalantarhormozi M, Larijani B, et al. Osteoprotegerin in relation to type 2 diabetes mellitus and the metabolic syndrome in postmenopausal women. Metabolism. 2010 ; 59: 742-747
5. Liu JJ, Tavintharan S, Yeoh LY, et al. High normal albuminuria is independently associated with aortic stiffness in patients with type 2 diabetes. Diabet Med. :
6. Tavintharan S, Ning C, Su Chi L, et al. Prevalence and risk factors for peripheral artery disease in an Asian population with diabetes mellitus. Diab Vasc Dis Res. 2009 ; 6: 80-86
7. Tan CE, Ma S, Wai D, et al. Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians?. Diabetes Care. 2004 ; 27: 1182-1186
8. Akinci B, Celtik A, Yuksel F, et al. Increased osteoprotegerin levels in women with previous gestational diabetes developing metabolic syndrome. Diabetes Res Clin Pract. 2011 ; 91: 26-31
9. Xiang GD, Sun HL, Zhao LS. Changes of osteoprotegerin before and after insulin therapy in type 1 diabetic patients. Diabetes Res Clin Pract. 2007 ; 76: 199-206
10. Xiang GD, Pu JH, Zhao LS, et al. Association between plasma osteoprotegerin concentrations and urinary albumin excretion in Type 2 diabetes. Diabet Med. 2009 ; 26: 397-403
11. Helas S, Goettsch C, Schoppet M, et al. Inhibition of receptor activator of NF-kappaB ligand by denosumab attenuates vascular calcium deposition in mice. Am J Pathol. 2009 ; 175: 473-478
12. Callegari A, Coons M, Ricks JL, et al. Bone marrow- or vessel wall-derived osteoprotegerin is sufficient to reduce atherosclerotic lesion size and vascular calcification. Arterioscler Thromb Vasc Biol. 2013 ; 33: 2491-2500